Related Experiment Video
Updated: Jul 1, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Real-World Impact of a Simplified 'Test and Treat' Strategy for In-Hospital HCV Micro-Elimination
Chunfang You1,2, Yuting Diao1, Juan Tang1
1Department of Infectious Diseases, Zigong First People's Hospital, Zigong, Sichuan Province, China.
Journal of Viral Hepatitis
|February 10, 2026
Summary
A simplified Hepatitis C virus (HCV)
Area of Science:
- Hepatology and Viral Hepatitis Research
- Public Health and Epidemiology
- Infectious Disease Management
Background:
- Hepatitis C virus (HCV) micro-elimination is hindered by fragmented care, high prevalence, and socioeconomic factors.
- Challenges include complex genotypes and barriers to accessing treatment in high-risk populations.
- Existing care pathways often lead to delays in diagnosis and treatment initiation.
Purpose of the Study:
- To evaluate a simplified 'Test and Treat' (TNT) strategy for enhancing in-hospital HCV micro-elimination.
- To assess the impact of TNT on HCV RNA testing rates, treatment uptake, and time to treatment.
- To identify barriers to treatment among patients with HCV.
Main Methods:
- A comparative study of pre-TNT (Jan. 2022-Dec. 2022) and post-TNT (Jan. 2023-Dec. 2024) periods.
- Analysis of HCV RNA testing rates, treatment uptake, time to treatment, and sustained virological response (SVR12).
- Surveys and follow-ups were conducted to investigate barriers among untreated patients.
Main Results:
- HCV RNA testing increased from 68.17% to 93.96%; treatment uptake rose from 63.05% to 81.98%.
- Median time to treatment initiation decreased significantly from 12.5 to 3.8 days.
- Sustained virological response at 12 weeks (SVR12) remained high at 99.71%.
Conclusions:
- The in-hospital TNT strategy significantly improved HCV testing, treatment linkage, and reduced treatment initiation time.
- Near-universal cure rates were achieved, exceeding WHO targets.
- Addressing affordability and health literacy is crucial for further progress in HCV micro-elimination.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:06Drug Elimination: The Concept of Clearance
Drug elimination refers to removing drugs from the body, either through urine by the kidneys or through bile by the liver. Drug clearance is a pharmacokinetic parameter that measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the plasma concentration of the drug.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination,...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Automated Microbial Diagnostics
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...